We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

ORASURE TECHNOLOGIES

OraSure Technologies develops, manufactures and distributes oral fluid diagnostic and collection devices and other te... read more Featured Products: More products

Download Mobile App




OraSure Technologies Acquires Sherlock Biosciences

By LabMedica International staff writers
Posted on 23 Dec 2024

OraSure Technologies (Bethlehem, PA, USA), a leader in point-of-need and at-home diagnostic tests and sample management solutions, has acquired Sherlock Biosciences (Watertown, MA, USA), a global health company that develops next-generation diagnostics for consumers and healthcare providers. More...

This acquisition enhances OraSure’s innovation pipeline with the addition of Sherlock’s molecular diagnostics platform, which provides rapid, highly sensitive, and specific results in a disposable format ideal for over-the-counter use.

Sherlock's first molecular self-test targets Chlamydia Trachomatis (CT) and Neisseria Gonorrhoeae (NG), which will broaden OraSure's portfolio of rapid diagnostics for sexually transmitted infections (STIs), pending regulatory approvals. The test promises results in under 30 minutes by analyzing DNA and RNA from self-collected swabs using isothermal amplification. Furthermore, Sherlock is developing a range of molecular tests and next-generation technology platforms, including Ambient Temperature Amplification and CRISPR-based technologies, which could lower costs and improve the performance of its diagnostic platforms.

Currently undergoing clinical studies, Sherlock’s CT/NG self-test is expected to be submitted to the FDA by the end of 2025 for approval. Pending regulatory clearance, this test is anticipated to drive OraSure's growth, beginning in 2026, through its established infrastructure, commercial capabilities, and robust customer relationships. The total addressable market for CT/NG testing is estimated at over USD 1.5 billion. Presently, most CT/NG tests in the U.S. are processed in centralized laboratories, and the launch of an affordable, fast self-test could significantly expand the market. Additionally, public health channels are crucial to STI screening, an area where OraSure already has a strong presence.

“The acquisition of Sherlock represents the next step in OTI’s innovation strategy,” said Carrie Eglinton Manner, President and CEO of OraSure. “Sherlock brings valuable capabilities with an advanced molecular platform that aims to deliver lab-like accuracy in a format that expands access to diagnostic insights through convenient, effortless tests. We are excited to welcome Sherlock’s talented team to OTI and believe that Sherlock’s unique capabilities will contribute significantly to the expansion of our pipeline of diagnostic tests in infectious disease, sexual health, and beyond.”

Related Links:
OraSure Technologies
Sherlock Biosciences


New
Gold Member
Thyroid-Stimulating Hormone Test
ULTRA-TSH
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Mumps Test
ReQuest MUMPS IgM Assay
New
C-Reactive Protein Rapid Test
Afinion CRP
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The POC device rapidly predicts neonatal respiratory disease at birth in the NICU (Photo courtesy of SIME Diagnostics)

AI-Powered Lung Maturity Test Identifies Newborns at Higher Risk of Respiratory Distress

Each year, approximately 300,000 babies in the United States are born between 32 and 36 weeks' gestation, according to national health data. This group is at an elevated risk for respiratory distress,... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: A biomarker discovery pipeline has shown promise as a noninvasive method of diagnosing CRC (Photo courtesy of NCI Center for Cancer Research)

Machine Learning Tool Enables Noninvasive Diagnosis and Monitoring of Colorectal Cancer

Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the United States when considering both genders. Colonoscopy remains the gold standard for CRC diagnosis, but it is invasive,... Read more

Technology

view channel
Image: Scanning electron microscopy images showing 3D micro-printed Limacon-shaped whispering-gallery-mode microcavities with different amounts of deformation (Photo courtesy of A. Ping Zhang/PolyU)

Tiny Microlaser Sensors with Supercharged Biosensing Ability to Enable Early Disease Diagnosis

Optical whispering-gallery-mode microlaser sensors function by trapping light within tiny microcavities. When target molecules bind to the cavity, they induce subtle changes in the laser’s frequency, allowing... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.